- Home
- ZLAB vs ERO Comparison
ZLAB vs ERO Comparison
Compare ZLAB & ERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZLAB | ERO |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.8B |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ZLAB | ERO |
|---|---|---|
| Price | $18.40 | $30.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $49.60 | $36.50 |
| AVG Volume (30 Days) | 659.7K | ★ 792.4K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.46 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $460,156,000.00 | N/A |
| Revenue This Year | $9.75 | $51.94 |
| Revenue Next Year | $26.03 | $2.43 |
| P/E Ratio | ★ N/A | $22.61 |
| Revenue Growth | ★ 15.33 | N/A |
| 52 Week Low | $15.96 | $13.37 |
| 52 Week High | $38.72 | $39.80 |
Technical Indicators
Market Signals| Indicator | ZLAB | ERO |
|---|---|---|
| Relative Strength Index (RSI) | 42.59 | 66.15 |
| Support Level | $18.29 | $27.82 |
| Resistance Level | $19.41 | $32.52 |
| Average True Range (ATR) | 0.60 | 1.06 |
| MACD | -0.20 | 0.55 |
| Stochastic Oscillator | 15.45 | 97.88 |
Price Performance
Historical ComparisonAbout ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
About ERO Ero Copper Corp.
Ero Copper Corp is a high-margin, high-growth copper producer with operations in Brazil. Its primary asset is its 99.6% ownership interest in Mineracao Caraiba S.A., held indirectly through its wholly-owned subsidiary. The company also owns a 97.6% ownership interest in NX Gold S.A. indirectly through its wholly-owned subsidiary. Its reporting segments include its three operating mines in Brazil, the Caraiba Operations, the Tucuma Operation, and the Xavantina Operations, and its corporate head office in Canada.